Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1087
Gene Symbol: CEACAM7
CEACAM7
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE CEA response merits further investigation as a surrogate endpoint of clinical trials of first-line medical therapy of patients with mCRC, and should be studied as a prognostic factor for those patients who are candidates for multimodal treatment strategies. 30671635

2019

Entrez Id: 1087
Gene Symbol: CEACAM7
CEACAM7
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Measurements of tumor markers, CEA and CA 19-9, in patients with metastatic colorectal cancer (<i>n</i> = 73) who received cetuximab plus folinic acid, fluorouracil, and oxaliplatin or irinotecan (FOLFOX4/FOLFIRI) as a first-line treatment at our center were retrospectively analyzed. 30805037

2019

Entrez Id: 1087
Gene Symbol: CEACAM7
CEACAM7
Secondary malignant neoplasm of colon and/or rectum
0.100 AlteredExpression BEFREE Progression-free and overall survival of 41 mCRC patients enrolled in the study correlated with baseline levels of CEA, immune-inflammatory markers (neutrophil/lymphocyte ratio, CRP, ESR, LDH, ENA), IL-4 and with post-treatment change in p-ANCA and CD56<sup>dim</sup>CD16<sup>bright</sup>NKs (<i>p</i> < 0.04). 29755670

2018

Entrez Id: 1087
Gene Symbol: CEACAM7
CEACAM7
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Our results show GDF-15 as an effective biomarker in patients with metastatic colorectal cancer with the same sensitivity as CEA. 29400662

2018

Entrez Id: 1087
Gene Symbol: CEACAM7
CEACAM7
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Baseline serum OPG correlated with CEA (r=0.36, p=0.0011), but independently predicted survival of mCRC patients. 29402836

2018

Entrez Id: 1087
Gene Symbol: CEACAM7
CEACAM7
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer. 29064002

2017

Entrez Id: 1087
Gene Symbol: CEACAM7
CEACAM7
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). 27234640

2016

Entrez Id: 1087
Gene Symbol: CEACAM7
CEACAM7
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer. 25608838

2015

Entrez Id: 1087
Gene Symbol: CEACAM7
CEACAM7
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE A phase 1/2 clinical trial evaluating dosing, safety, immunogenicity, and overall survival on metastatic colorectal cancer (mCRC) patients after immunotherapy with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine was performed. 25956394

2015

Entrez Id: 1087
Gene Symbol: CEACAM7
CEACAM7
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Carcinoembryonic antigen (CEA, CEACAM5) and epithelial cadherin (E-cadherin) are considered as independent tumor markers in monitoring metastatic colorectal cancer. 24726916

2014

Entrez Id: 1087
Gene Symbol: CEACAM7
CEACAM7
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE In the present study, we aimed to determine the prognostic role of initial CEA and CA 19-9 values in metastatic colorectal cancer patients according to the status of K-ras. 23625655

2013

Entrez Id: 1087
Gene Symbol: CEACAM7
CEACAM7
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. 23657083

2013